Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.18 EPS.

Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $6.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, February 5th.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN:LCTX opened at $1.18 on Monday. Lineage Cell Therapeutics has a one year low of $0.84 and a one year high of $1.61. The stock has a market capitalization of $222.78 million, a PE ratio of -9.08 and a beta of 1.39.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The company had revenue of $2.09 million during the quarter, compared to analysts’ expectations of $4.74 million. Lineage Cell Therapeutics had a negative return on equity of 31.95% and a negative net margin of 240.20%. As a group, sell-side analysts predict that Lineage Cell Therapeutics will post -0.13 EPS for the current year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Fifth Third Wealth Advisors LLC acquired a new stake in Lineage Cell Therapeutics in the first quarter valued at $30,000. DCF Advisers LLC lifted its holdings in Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after acquiring an additional 12,000 shares during the period. SG Americas Securities LLC lifted its holdings in Lineage Cell Therapeutics by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 30,889 shares of the company’s stock valued at $34,000 after acquiring an additional 11,779 shares during the period. Finally, Rathbones Group PLC acquired a new stake in shares of Lineage Cell Therapeutics in the 3rd quarter worth approximately $41,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.